Cost- and time-effective markers of Alzheimer’s disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N = 33) are significantly lower (p < 0.01) than those of cognitively healthy elderly individuals without AD (N = 39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.
Jack CRJR, KnopmanDS, WeigandSD, WisteHJ, VemuriP, LoweV, KantarciK, GunterJL, SenjemML, IvnikRJ, RobertsRO, RoccaWA, BoeveBF, PetersenRC (2012) An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol71, 765–775.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, Jack CRJR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
4.
Jack CRJR, BennettDA, BlennowK, CarrilloMC, DunnB, HaeberleinSB, HoltzmanDM, JagustW, JessenF, KarlawishJ, LiuE, MolinuevoJL, MontineT, PhelpsC, RankinKP, RoweCC, ScheltensP, SiemersE, SnyderHM, SperlingR (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement14, 535–562.
5.
AlexopoulosP, SirinianC (2018) Cerebrospinal fluid biomarkers of preclinical Alzheimer’s disease. In Biomarkers for preclinical Alzheimer’s disease,
PerneczkyR, ed. Humana Press, Springer, New York, pp. 93–106.
6.
AlexopoulosP, ThierjungN, GrimmerT, OrtnerM, EconomouP, AssimakopoulosK, GourzisP, PolitisA, PerneczkyR (2018) Cerebrospinal fluid BACE1 activity and sAbetaPPbeta as biomarker candidates of Alzheimer’s disease. Dement Geriatr Cogn Disord45, 152–161.
7.
Sheikh-BahaeiN, SajjadiSA, ManavakiR, GillardJH (2017) Imaging biomarkers in Alzheimer’s disease: A practical guide for clinicians. J Alzheimers Dis Rep1, 71–88.
8.
FrisoniGB, HanssonO (2016) Clinical validity of CSF biomarkers for Alzheimer’s disease: Necessary indeed, but sufficient?Lancet Neurol15, 650–651.
9.
RitchieC, SmailagicN, Noel-StorrAH, UkoumunneO, LaddsEC, MartinS (2017) CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev3, CD010803.
10.
SkillbäckT, FarahmandBY, RosénC, MattssonN, NäggaK, KilanderL, ReligaD, WimoA, WinbladB, SchottJM, BlennowK, EriksdotterM, ZetterbergH (2015) Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain138, 2716–2731.
11.
GabelleA, DumurgierJ, VercruysseO, PaquetC, BomboisS, LaplancheJ-L, Peoc’hK, SchraenS, BuéeL, PasquierF, HugonJ, TouchonJ, LehmannS (2013) Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: The PLM Study. J Alzheimers Dis34, 297–305.
12.
PerneczkyR, AlexopoulosP, KurzA (2014) Soluble amyloid precursor proteins and secretases as Alzheimer’s disease biomarkers. Trends Mol Med20, 8–15.
13.
O’BryantSE, MielkeMM, RissmanRA, ListaS, VandersticheleH, ZetterbergH, LewczukP, PosnerH, HallJ, JohnsonL, FongY-L, LuthmanJ, JerominA, Batrla-UtermannR, VillarrealA, BrittonG, SnyderPJ, HenriksenK, GrammasP, GuptaV, MartinsR, HampelH (2017) Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement13, 45–58.
14.
KoyamaA, OkerekeOI, YangT, BlackerD, SelkoeDJ, GrodsteinF (2012) Plasma amyloid-beta as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch Neurol69, 824–831.
15.
OlssonB, LautnerR, AndreassonU, OhrfeltA, PorteliusE, BjerkeM, HolttaM, RosenC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.
LewczukP, PoppJ, LelentalN, KölschH, MaierW, KornhuberJ, JessenF (2012) Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer’s disease. J Alzheimers Dis28, 119–125.
22.
MulugetaE, LondosE, HanssonO, BallardC, SkogsethR, MinthonL, BlennowK, ZetterbergH, AarslandD (2011) Cerebrospinal fluid levels of sAPPα and sAPPβ in Lewy body and Alzheimer’s disease: Clinical and neurochemical correlates. Int J Alzheimers Dis2011, 495025.
23.
ArakiW, ArakiYM, MizusawaH (2018) Potential value of soluble APP α and APP β in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives. Neurol Clin Neurosci6, 89–93.
24.
ArakiW, HattoriK, KanemaruK, YokoiY, OmachiY, TakanoH, SakataM, YoshidaS, TsukamotoT, MurataM, SaitoY, KunugiH, GotoY-i, NagaokaU, NagaoM, KomoriT, ArimaK, IshiiK, MurayamaS, MatsudaH, TachimoriH, ArakiYM, MizusawaH (2017) Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders. Biomark Res5, 28.
25.
PerneczkyR, AlexopoulosP (2014) Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer’s disease. Alzheimers Dement10, S425–S429.e1.
AlexopoulosP, GuoL-H, JiangM, BujoH, GrimmerT, ForsterS, DrzezgaA, KurzA, PerneczkyR (2013) Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer’s disease cerebral metabolic signature. J Alzheimers Dis36, 401–408.
30.
VandermeerenM, MerckenM, VanmechelenE, SixJ, van de VoordeA, MartinJJ, CrasP (1993) Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem61, 1828–1834.
31.
VandersticheleH, van KerschaverE, HesseC, DavidssonP, BuyseMA, AndreasenN, MinthonL, WallinA, BlennowK, VanmechelenE (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid7, 245–258.
32.
HulstaertF, BlennowK, IvanoiuA, SchoonderwaldtHC, RiemenschneiderM, DeynPP de, BancherC, CrasP, WiltfangJ, MehtaPD, IqbalK, PottelH, VanmechelenE, VandersticheleH (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology52, 1555–1562.
33.
PerneczkyR, AlexopoulosP (2018) Soluble amyloid precursor proteins in blood: Methods and challenges. In Biomarkers for preclinical Alzheimer’s disease,
PerneczkyR, ed., Humana Press, Springer, New York, pp. 179–187.
34.
WerleLB (2015) Lösliches Amyloidvorläuferprotein Beta als Biomarker für die Alzheimer-Krankheit, Dissertation, Munich.
35.
MandeckaM, BudziszewskaM, BarczakA, PeplonskaB, Chodakowska-ZebrowskaM, Filipek-GliszczynskaA, NesterukM, StyczynskaM, BarcikowskaM, GabryelewiczT (2016) Association between cerebrospinal fluid biomarkers for Alzheimer’s disease, APOE genotypes and auditory verbal learning task in subjective cognitive decline, mild cognitive impairment, and Alzheimer’s disease. J Alzheimers Dis54, 157–168.
36.
YiD, LeeY, ByunMS, LeeJH, KoK, SohnBK, ChoeYM, ChoiHJ, BaekH, SohnC-H, KimYK, LeeDY (2018) Synergistic interaction between APOE and family history of Alzheimer’s disease on cerebral amyloid deposition and glucose metabolism. Alzheimers Res Ther10, 84.
37.
WenhamPR, PriceWH, BlandellG (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet337, 1158–1159.
38.
TobinJ (1958) Estimation of relationships for limited dependent variables. Econometrica26, 24.
39.
WuG, SankaranarayananS, HsiehSH-K, SimonAJ, SavageMJ (2011) Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer’s disease cortex. J Neurosci Res89, 822–832.
40.
LotzA, KendziaB, GawrychK, LehnertM, BrüningT, PeschB (2013) Statistical methods for the analysis of left-censored variables, GMS Medizinische Informatik, Biometrie und Epidemiologie; 9(2): Doc05; ISSN 1860-9171.
41.
WangJ, GuBJ, MastersCL, WangY-J (2017) A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol13, 612.
42.
LiuY-H, WangY-R, XiangY, ZhouH-D, GiuntaB, Mañucat-TanNB, TanJ, ZhouX-F, WangY-J (2015) Clearance of amyloid-beta in Alzheimer’s disease: Shifting the action site from center to periphery. Mol Neurobiol51, 1–7.
43.
MehtaPD, PirttilaT, MehtaSP, SersenEA, AisenPS, WisniewskiHM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol57, 100–105.
44.
MawuenyegaKG, SigurdsonW, OvodV, MunsellL, KastenT, MorrisJC, YarasheskiKE, BatemanRJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science330, 1774.
